Zacks Research Issues Negative Outlook for Sanofi Earnings

Sanofi (NASDAQ:SNY) – Analysts at Zacks Research decreased their Q4 2025 earnings estimates for Sanofi in a research note issued on Tuesday, October 15th. Zacks Research analyst K. Shah now anticipates that the company will post earnings per share of $1.23 for the quarter, down from their prior forecast of $1.24. The consensus estimate for Sanofi’s current full-year earnings is $4.26 per share. Zacks Research also issued estimates for Sanofi’s Q3 2026 earnings at $1.35 EPS.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. The company had revenue of $10.75 billion for the quarter, compared to analysts’ expectations of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. Sanofi’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.95 EPS.

A number of other analysts have also recently issued reports on the stock. Argus raised their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday, October 14th. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Trading Up 0.1 %

Shares of Sanofi stock opened at $54.93 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The business has a fifty day simple moving average of $56.11 and a two-hundred day simple moving average of $51.55. Sanofi has a 1 year low of $42.63 and a 1 year high of $58.97. The company has a market capitalization of $139.12 billion, a price-to-earnings ratio of 27.60, a P/E/G ratio of 1.57 and a beta of 0.60.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. POM Investment Strategies LLC acquired a new stake in Sanofi during the second quarter worth approximately $25,000. Register Financial Advisors LLC bought a new position in shares of Sanofi in the first quarter worth $29,000. Larson Financial Group LLC raised its stake in Sanofi by 480.8% in the first quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after purchasing an additional 500 shares in the last quarter. Palisade Asset Management LLC bought a new stake in Sanofi during the first quarter worth about $31,000. Finally, Arrow Financial Corp acquired a new stake in Sanofi during the second quarter worth about $35,000. 10.04% of the stock is owned by institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.